Electronic ISSN 2287-0237



  1. Siegel R, Miller K, Jemal A. Cancer Statistic, 2017. CACancer J Clin 2017;67:7-30.
  2. American Cancer Society. Cancer Facts & Figures 2018.Atlanta, Ga: American Cancer Society; 2018.
  3. Gambhir SS, Czermin J, Schwimmer J, et al. A tabulatedsummary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
  4. Bouchelouche K, Tagawa ST, Goldsmith SJ, et al. PET/CTImaging and Radioimmunotherapy of Prostate Cancer. SeminNucl Med. 2011;41:29-44.
  5. Evangelista L, Guttilla A, Zatttoni F, et al. Utility of cholinepositron emission tomography/computed tomography forlymph node involvement identification in intermediate- tohigh-risk prostate cancer: a systematic literature review andmeta-analysis. Eur Urol. 2013;63:1040-8.
  6. Silver DA, Pellicer I, Fair WR, et al. Prostate-specificmembrane antigen expression in normal and malignant humantissues. Clin Cancer Res. 1997;3:81-5
  7. Mannweiler S, Amersdorfer P, Trajanoski S, et al. Heterogeneityof prostate-specific membrane antigen (PSMA) expression inprostate carcinoma with distant metastasis. Path Oncol Res.2009;15:167-72.
  8. Bostwick DG, Pacelli A, Blute M, et al. Prostate specificmembrane antigen expression in prostatic intraepithelialneoplasia and adenocarcinoma: a study of 184 cases. Cancer.1998;82:2256-61.
  9. Troyer JK, Beckett ML, Wright GL. Detection and characterizationof the prostate-specific membrane antigen (PSMA) intissue extracts and body fluids. Int J Cancer. 1995;62:552-8.
  10. Sterzing F, et al. 68Ga-PSMA-11 PET/CT: a new techniquewith high potential for the radiotherapeutic management ofprostate cancer patients. Eur J Nucl Med Mol Imaging.2016;43:34-41.
  11. Ghosh A, Heston W.D. Tumor target prostate specificmembrane antigen (PSMA) and its regulation in prostatecancer. J Cell Biochem. 2004;91:528-39.
  12. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonalantibodies to a new antigenic marker in epithelial prostaticcells and serum of prostatic cancer patients.Anticancer Res.1987;7:927-35.
  13. Foss CA, et al. Radiolabeled small-molecule ligands forprostate-specific membrane antigen; in vivo imaging inexperimental models of prostate cancer. Clin Cancer Res.2005;11:4022-8.14.
  14. Hillier S. M. et al. Preclinical evaluation of novelglutamate-urea-lysine analogues that target prostate-specificmembrane antigen as molecular imaging pharmaceuticals forprostate cancer. Cancer Res. 2009;69:6932-40.
  15. Kularatne SA, Zhou Z, Yang J, et al. Design, synthesis andpreclinical evaluation of prostate-specific membrane antigentargeted 99mTc-radioimaging agents. Mol Pharm. 2009;6:790-800.
  16. Rowe S. P, et al. PSMA-Based [18F]DCFPyL PET/CT IsSuperior to Conventional Imaging for Lesion Detection inPatients with Metastatic Prostate Cancer. Mol Imaging Biol.2016;18:411-9.
  17. Chen Y. et al. 2-(3-{1-carboxy-5-[(6-[19F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyl, a PSMA-based PET imaging agent for prostatecancer. Clin Cancer Res. 2011;17:7645-53.
  18. Giesel FL, et al. F-18 labelled PSMA-1007: biodistribution,radiation dosimetry and histopathological validation of tumorlesions in prostate cancer patients. Eur J Nucl Mol Imaging.2017;44:678-88.
  19. Benerjee SR. et al. A modular strategy to prepare multivalentinhibitors of prostate-specific membrane antigen (PSMA).Oncotarget. 2011;2:1244-53.
  20. Afshar-Oromieh A. et al. The diagnostic value of PET/CTimaging with the (68)Ga-labelled PSMA ligand HBED-CCin the diagnosis of recurrent prostate cancer. Eur J Nucl MedMol Imaging. 2015;42:197-209.
  21. Kallur KG., et al. Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer. Indian J Nucl Med. 2017;32:110-7.
  22. Uprimny C, et al. Early PET imaging with [68]Ga-PSMA-11increases the detection rate of local recurrence in prostatecancer patients with biochemical recurrence. Eur J Nucl MedMol Imaging. 2017; 44:1647-55.
  23. Kesch C, et al. 68Ga or 18F for Prostate Cancer Imaging? JNucl Med. 2017;58:687-8.
  24. Rowe SP., et al. PET imaging of prostate-specific membraneantigen in prostate cancer: current state of the art and futurechallenges. Prostate Cancer Prostatic Dis. 2016;19:223-30.
  25. Lutje S, et al. PSMA Ligands for Radionuclide Imaging andTherapy of Prostate Cancer: Clinical Status. Theranostics.2015;5:1388-401.
  26. Chen Y, et al. Synthesis and biological evaluation of lowmolecular weight fluorescent imaging agents for the prostatespecificmembrane antigen. Bioconjug Chem 2012; 23:2377-85.
  27. Eder M, et al. Tetrafluorophenolate of HBED-CC: A versatileconjugation agent for 68Ga-labeled small recombinant antibodies.Eur J Nucl Med Mol Imaging 2008;35:1878-86.
  28. Eberhan T, et al. Development of a Single Vial Kit Solutionfor Radiolabeling of 68Ga-DKFZ-PSMA-11 and ItsPerformance in Prostate Cancer Patients. Molecules. 2015;20:14860-78.
  29. Satpati D, et al. Convenient Preparation of [(68)Ga]DKFZPSMA-11 Using a Robust Single-Vial Kit and Demonstrationof Its Clinical Efficacy. Mol Imaging Biol. 2016; 18:420-7.
  30. Weineisen M, Simecek J, Schottelius M, et al. Synthesis andpreclinical evaluation of DOTAGA-conjugated PSMA ligandsfor functional imaging and endoradiotherapy of prostatecancer. EJNMMI Res. 2014;4:63.
  31. Ahmadzadehfar H, Eppard E, Kürpig S et al. Therapeuticresponse and side effects of repeated radioligand therapy with177Lu-PSMA-DKFZ-617 of castrate resistant metastaticprostate cancer. Oncotarget 2016;7:12477-88.
  32. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. Germanmulticenter study investigating 177Lu-PSMA-617 radioligandtherapy in advanced prostate cancer patients. J Nucl Med2017;58:85-90.